Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NGM BIOPHARMACEUTICALS, INC.

(NGM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NGM Biopharmaceuticals : Developing NGM831 to Treat Cancer

08/23/2021 | 12:56pm EST


ę MT Newswires 2021
All news about NGM BIOPHARMACEUTICALS, INC.
11/09NGM Bio to Participate in Upcoming Investor Conferences
GL
11/04NGM BIOPHARMACEUTICALS : Q3 Earnings Snapshot
AQ
11/04NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results -..
PU
11/04NGM BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition..
AQ
11/04NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
11/04NGM BIOPHARMACEUTICALS INC : Results of Operations and Financial Condition (form 8-K)
AQ
11/04NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results
AQ
09/17NGM BIOPHARMACEUTICALS : BMO Capital Raises Price Target on NGM Biopharmaceuticals to $35 ..
MT
09/16NGM BIOPHARMACEUTICALS : Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose E..
AQ
09/16NGM Biopharmaceuticals, Inc. Presents Preliminary Findings from Ongoing Phase 1A/1B Dos..
CI
More news
Analyst Recommendations on NGM BIOPHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 77,6 M - -
Net income 2021 -121 M - -
Net cash 2021 153 M - -
P/E ratio 2021 -11,5x
Yield 2021 -
Capitalization 1 400 M 1 400 M -
EV / Sales 2021 16,1x
EV / Sales 2022 29,9x
Nbr of Employees 210
Free-Float 70,5%
Chart NGM BIOPHARMACEUTICALS, INC.
Duration : Period :
NGM Biopharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NGM BIOPHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 18,02 $
Average target price 35,50 $
Spread / Average Target 97,0%
EPS Revisions
Managers and Directors
David J. Woodhouse Chief Executive Officer & Director
Siobhan Nolan Mangini CFO & Principal Accounting Officer
William J. Rieflin Executive Chairman
Hui Tian Vice President-Research
Marc Learned Vice President-Research Operations
Sector and Competitors
1st jan.Capi. (M$)
NGM BIOPHARMACEUTICALS, INC.-42.14%1 362
GILEAD SCIENCES, INC.21.27%88 622
BIONTECH SE344.70%87 556
REGENERON PHARMACEUTICALS35.46%68 421
WUXI APPTEC CO., LTD.28.27%66 062
VERTEX PHARMACEUTICALS-19.56%48 336